How do VKORC1 and CYP2C9 gene polymorphisms influence warfarin therapy?

• A. They have no impact.
• B. They influence sensitivity and metabolism; certain haplotypes require lower dosing; genotype-guided dosing can reduce extreme INR values.
• C. They only affect bleeding risk, not dosing.
• D. They only affect INR if combined with vitamin K intake.

Answer: (C)

Warfarin response is largely shaped by genetics. VKORC1 and CYP2C9 are the two major players because they control how strongly the drug works and how quickly it is cleared from the body. VKORC1 encodes the target of warfarin, vitamin K epoxide reductase. Variants that reduce the activity of this enzyme make the patient more sensitive to warfarin, so a lower dose is needed to achieve the same anticoagulant effect. CYP2C9 encodes the liver enzyme that metabolizes the more potent S-enantiomer of warfarin. Variants that reduce CYP2C9 activity slow drug clearance, causing higher drug exposure for any given dose and raising the risk of over-anticoagulation.

When both types of variants are present, the effect compounds: people may require substantially lower maintenance doses and slower titration to reach a safe therapeutic range. Using genotype information to guide initial dosing and adjustments can shorten the time to a stable INR and reduce the likelihood of extreme INRs, which are associated with bleeding or thrombosis risk.

These genes do not have no impact, nor do they affect only bleeding risk. They influence dosing through both sensitivity and metabolism, and their impact persists regardless of vitamin K intake, though diet can modulate warfarin effect. Genotype-guided dosing is a tool clinicians use to tailor therapy and minimize safety concerns during initiation and maintenance.